References of "Revue Médicale de Liège"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailTomographie a emission de positons au 18FDG et adenocarcinome pancreatique
Daenen, Frédéric ULg; Hustinx, Roland ULg; Belhocine, Tarik et al

in Revue Médicale de Liège (2000), 55(2), 89-94

FDG-PET imaging non invasively studies the glucose metabolism which is usually increased in malignant lesions. We evaluated the clinical performance of PET for detecting pancreatic cancer and its ... [more ▼]

FDG-PET imaging non invasively studies the glucose metabolism which is usually increased in malignant lesions. We evaluated the clinical performance of PET for detecting pancreatic cancer and its recurrence. In our series of 24 studies, PET appears to complement other imaging modalities. As compared to CT, in particular, it demonstrated fewer false positive results in the pancreas and it was also more sensitive. Moreover, whole-body FDG-PET allows for the entire staging of the disease. [less ▲]

Detailed reference viewed: 30 (0 ULg)
Peer Reviewed
See detailComment j'explore ... la dissection de l'aorte thoracique
Hubin, L.; Hoffer, E.; Ghaye, Benoît ULg et al

in Revue Médicale de Liège (2000), 55(1), 49-56

Thoracic aortic dissection constitutes an acute pathology that requires a rapid, accurate and reliable diagnosis. The authors describe and illustrate the advantages and limitations of imaging modalities ... [more ▼]

Thoracic aortic dissection constitutes an acute pathology that requires a rapid, accurate and reliable diagnosis. The authors describe and illustrate the advantages and limitations of imaging modalities used in this pathology. [less ▲]

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailMise au point d'une hyperparathyroidie primitive: apport de la scintigraphie
Brasseur, Edmond ULg; PHILIPS, Jean-Christophe ULg; BELHOCINE, Tarik et al

in Revue Médicale de Liège (2000), 55(1), 39-44

We report a case of hyperparathyroidism whose diagnosis was suspected by a clinical history and confirmed by routine laboratory tests. Scintigraphy has permitted to localize a focalized lesion ... [more ▼]

We report a case of hyperparathyroidism whose diagnosis was suspected by a clinical history and confirmed by routine laboratory tests. Scintigraphy has permitted to localize a focalized lesion corresponding to an adenoma endocrinopathy. The new developments of this imaging technique will be discussed further. Some aspects of physiopathology will be briefly considered and a therapeutic algorithm will be proposed. [less ▲]

Detailed reference viewed: 17 (0 ULg)
Peer Reviewed
See detailInfo-congres. Recherche en diabetologie: rayonnement europeen de l'Ecole de Liege.
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(10), 960-7

Detailed reference viewed: 12 (1 ULg)
Peer Reviewed
See detailInfo-congres. L'etude "MIRACL" ou "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering".
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(12), 1064-6

The results of the "MIRACL" trial ("Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering") were presented at the recent annual meeting of the American Heart Association in New Orleans last ... [more ▼]

The results of the "MIRACL" trial ("Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering") were presented at the recent annual meeting of the American Heart Association in New Orleans last November 2000. This study demonstrates that atorvastatin, at a daily dose of 80 mg starting within the first 24 to 96 hours after an acute coronary event (unstable angina or non-Q-wave acute myocardial infarction) and maintained for 4 months, improves the cardiovascular prognosis by decreasing the combined risk of death (any cause), nonfatal myocardial infarction, resuscitated cardiac arrest and worsening angina with new objective evidence of ischemia requiring urgent hospitalization (-16% versus placebo, p < 0.05). [less ▲]

Detailed reference viewed: 58 (2 ULg)
Peer Reviewed
See detailOestrogenotherapie apres la menopause et protection cardio-vasculaire: discordance entre les observations epidemiologiques et les resultats d'essais therapeutiques.
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(9), 886-8

Based upon the positive results of a large epidemiological study and the negative results of an interventional clinical trial recently published in the New England Journal of Medicine, we will briefly ... [more ▼]

Based upon the positive results of a large epidemiological study and the negative results of an interventional clinical trial recently published in the New England Journal of Medicine, we will briefly discuss the impact of estrogen replacement therapy on the protection against coronary heart disease in postmenopausal women. [less ▲]

Detailed reference viewed: 30 (1 ULg)
Peer Reviewed
See detailQuoi de neuf dans le domaine de l'obesite?
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(7), 756-9

We will briefly comment on some interesting topics presented at the 10th European Congress on Obesity (ECO, Antwerp, Belgium, 24-27 May 2000). Special attention has been focused upon: 1) the multi ... [more ▼]

We will briefly comment on some interesting topics presented at the 10th European Congress on Obesity (ECO, Antwerp, Belgium, 24-27 May 2000). Special attention has been focused upon: 1) the multi-endocrine function of the adipocyte cell; 2) the role of gene-environment interactions; 3) the regulatory mechanisms of energy balance; 4) the neuroendocrine hypothesis for the development of visceral adiposity; 5) the numerous complications associated with obesity, more particularly type 2 diabetes; and, finally, 6) obesity prevention, especially in childhood, and new pharmacological perspectives for the treatment of obesity. [less ▲]

Detailed reference viewed: 14 (1 ULg)
Peer Reviewed
See detailDe la medecine factuelle aux recommandations therapeutiques. Epilogue.
Scheen, André ULg; Kulbertus, Henri ULg

in Revue Médicale de Liège (2000), 55(5), 476-7

Detailed reference viewed: 21 (1 ULg)
Peer Reviewed
See detailQuelques considerations generales et rappels historiques a propos de la therapeutique.
Kulbertus, Henri ULg; Scheen, André ULg

in Revue Médicale de Liège (2000), 55(4), 201-5

Detailed reference viewed: 34 (2 ULg)
Peer Reviewed
See detailL'etude clinique du mois. L'apres DCCT, l'etude EDIC.
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(3), 187-9

The "Diabetes Control and Complications Trial" (DCCT) demonstrated that intensive insulin therapy, by reducing HbA1c levels by about 2%, delays the onset and slows the progression of microangiopathic ... [more ▼]

The "Diabetes Control and Complications Trial" (DCCT) demonstrated that intensive insulin therapy, by reducing HbA1c levels by about 2%, delays the onset and slows the progression of microangiopathic complications (by at least 50%) in patients with type 1 diabetes. The "Epidemiology of Diabetes Interventions and Complications" (EDIC) study recently showed that the reduction in the risk of progressive retinopathy and nephropathy resulting from intensive therapy during the DCCT not only persists, but is amplified for at least 4 years (reduction by about 80% when compared to diabetic patients previously treated with conventional therapy during the DCCT). [less ▲]

Detailed reference viewed: 49 (0 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. Le glimepiride (Amarylle).
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(3), 184-6

Glimepiride, commercialized in Belgium under the trade name of Amarylle by Aventis, is a new sulphonylurea compound which is indicated in the treatment of type 2 diabetes, after diet and exercise failure ... [more ▼]

Glimepiride, commercialized in Belgium under the trade name of Amarylle by Aventis, is a new sulphonylurea compound which is indicated in the treatment of type 2 diabetes, after diet and exercise failure. It is available as 2 mg tablets. The initial doses is 1 mg, to be progressively increased up to 4 mg per day, if necessary, with a maximal daily dose of 6 mg. It is recommended to take glimepiride once a day, with the first main meal. Because of a particular binding of this sulphonylurea to the B cells of Langerhans pancreatic islets and, perhaps, of the presence of some extrapancreatic effects, both hypoglycaemic risk and circulating plasma insulin levels are lower with glimepiride than with glibenclamide, the reference sulphonylurea agent used in comparative clinical trials. [less ▲]

Detailed reference viewed: 56 (0 ULg)
Peer Reviewed
See detailLe dosage des auto-anticorps anti-GAD et anti-IA 2: une aide au diagnostic precoce du diabete de type 1.
Luyckx, Françoise ULg; Delcourt, Sandrine ULg; Philips, Jean-Christophe ULg et al

in Revue Médicale de Liège (2000), 55(3), 169-75

Diabetes mellitus is a frequent metabolic disease characterised by a complex and inconstant phenotypic expression that complicates the classification of patients and sometimes delays their optimal ... [more ▼]

Diabetes mellitus is a frequent metabolic disease characterised by a complex and inconstant phenotypic expression that complicates the classification of patients and sometimes delays their optimal management. In that slowly progressive disease leading to severe and irreversible complications, the use of early and specific genetic, immunological and/or metabolic markers may help in the classification of diabetic patients and in the orientation of therapeutic strategies; furthermore, it is also an essential aid in the early screening of subjects at risk of developing the disease. The assessment of classical immunological markers, such as islet cell antibodies (ICA) or anti-insulin antibodies (IAA) has been recently completed by the screening of new promising markers such as GAD- and IA2-antibodies. The presence of these markers confirms the autoimmune component of the disease and thus supports the diagnosis of type 1 diabetes, even if clinical symptoms are absent or inconsistent. In addition, it represents a strong argument in favour of the initiation of specific immunological therapies to preserve B-cell number and function. [less ▲]

Detailed reference viewed: 474 (10 ULg)
Peer Reviewed
See detailL'etude clinique du mois. L'etude HOPE, un essai clinique bicephale aux resultats contrastes.
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(2), 121-4

The results of the HOPE ("Heart Outcomes Prevention Evaluation") study, recently published in the New England Journal of Medicine, demonstrated a highly significant cardiovascular protection by an ... [more ▼]

The results of the HOPE ("Heart Outcomes Prevention Evaluation") study, recently published in the New England Journal of Medicine, demonstrated a highly significant cardiovascular protection by an angiotensin converting enzyme inhibitor, ramipril at a dose of 10 mg/day, after a mean follow-up of 4.5 years, but not of vitamin E supplements at a dose of 400 UI/day in high-risk patients (> 55 years old) who had evidence of vascular disease (secondary prevention) or combined diabetes mellitus and another cardiovascular risk factor (primary prevention). [less ▲]

Detailed reference viewed: 82 (0 ULg)
Peer Reviewed
See detailPharma clinics. Le medicament du mois. La cerivastatine (Lipobay, Cholstat).
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(2), 117-20

Cerivastatin, commercialized under the trade names of Lipobay by Bayer and Cholstat by Fournier Pharma, is a new synthetic statin. Because of its high affinity for HMG-CoA reductase enzyme that it ... [more ▼]

Cerivastatin, commercialized under the trade names of Lipobay by Bayer and Cholstat by Fournier Pharma, is a new synthetic statin. Because of its high affinity for HMG-CoA reductase enzyme that it specifically and selectively inhibited in the hepatocytes, cerivastatin exerts its cholesterol-lowering effect at very low doses, between 0.1 and 0.3 mg/day. Cerivastatin is indicated, after diet failure, in the treatment of primary forms of isolated hypercholesterolaemia or combined hyperlipidaemia. It is presented by the two pharmaceutical companies as 0.1, 0.2 and 0.3 mg filmed tablets. Usual dose is 0.3 mg, once daily, to be reduced in presence of renal failure. Cerivastatin is metabolised within the liver by two different families of cytochrome P450, which limits the risk of drug interferences. Besides this potential advantage as compared with some other statins, its pharmacodynamic activity and safety profile seem to be similar to those of other agents of the same pharmacological family. [less ▲]

Detailed reference viewed: 35 (0 ULg)
Full Text
Peer Reviewed
See detailComment j'explore...une mycobactériose cutanée atypique
Henry, Frédérique ULg; Hayette, Marie-Pierre ULg; Melin, Pierrette ULg et al

in Revue Médicale de Liège (2000), 55(12), 1058-1063

Atypical mycobacteriosis affecting the skin are diverse and their treatments are different as well. These diseases show an increasing prevalence. The contamination occurs from the environment while ... [more ▼]

Atypical mycobacteriosis affecting the skin are diverse and their treatments are different as well. These diseases show an increasing prevalence. The contamination occurs from the environment while interhuman transmission does not occur. [less ▲]

Detailed reference viewed: 81 (6 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. La combinaison fixe dipyridamole--acide acetylsalicylique (Aggrenox).
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(10), 957-9

Aggrenox, launched in Belgium by Boehringer Ingelheim, is a fixed-dose combination of extended-release dipyridamole (200 mg) and aspirin (25 mg), two antiplatelet agents with different and complementary ... [more ▼]

Aggrenox, launched in Belgium by Boehringer Ingelheim, is a fixed-dose combination of extended-release dipyridamole (200 mg) and aspirin (25 mg), two antiplatelet agents with different and complementary mechanisms of action. It is recommended, twice daily, in the protection against secondary stroke and transient ischaemic attacks. The placebo-controlled European study ESPS 2 (European Stroke Prevention Study 2) demonstrated that the administration of this combination was twice as effective as either agent alone in the secondary prevention of stroke in patients with prior stroke or transient ischaemic attack. [less ▲]

Detailed reference viewed: 17 (0 ULg)
Peer Reviewed
See detailPharma-clinics. Le medicament du mois. La levofloxacine (Tavanic).
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(11), 1015-7

Levofloxacin, the (-)-(S)-enantiomer isolated from the racemate ofloxacin, is launched by Aventis under the trade name of Tavanic. This new oral and parenteral antibiotic belongs to the fluoroquinolone ... [more ▼]

Levofloxacin, the (-)-(S)-enantiomer isolated from the racemate ofloxacin, is launched by Aventis under the trade name of Tavanic. This new oral and parenteral antibiotic belongs to the fluoroquinolone family and exerts a bactericidal activity upon a large spectrum of microorganisms, including Gram negative and Gram positive bacilli (among which Streptococcus pneunomiae), and atypical respiratory pathogens. It also has interesting pharmacokinetic properties. Besides the classical indications of other fluoroquinolones (especially complicated urinary tract infections, including pyelonephritis, and severe skin and soft tissue infections), levofloxacin is indicated for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis and community-acquired pneumonia. [less ▲]

Detailed reference viewed: 102 (4 ULg)
Peer Reviewed
See detailComment j'explore ... les anomalies du metabolisme glucidique, de l'insulinosecretion et de la sensibilite a l'insuline avec une hyperglycemie provoquee par voie orale.
Luyckx, Françoise ULg; Scheen, André ULg

in Revue Médicale de Liège (2000), 55(9), 881-5

Oral glucose tolerance test (OGTT) has been widely used for the diagnosis of diabetes mellitus, gestational diabetes, impaired glucose tolerance or reactive hypoglycaemia. Simultaneous measurements of ... [more ▼]

Oral glucose tolerance test (OGTT) has been widely used for the diagnosis of diabetes mellitus, gestational diabetes, impaired glucose tolerance or reactive hypoglycaemia. Simultaneous measurements of plasma glucose and insulin levels also allow to derive indices of insulin secretion and insulin sensitivity. Whereas OGTT is not considered anymore as the first choice for the diagnosis of diabetes mellitus, it remains useful for studying abnormalities of glucose metabolism as well as of insulin secretion and insulin action. [less ▲]

Detailed reference viewed: 46 (0 ULg)
Peer Reviewed
See detailL'etude clinique du mois. Insulino-independance prolongee apres transplantation d'ilots de langerhans chez le patient diabetique de type 1: l'aboutissement d'un reve?
Scheen, André ULg

in Revue Médicale de Liège (2000), 55(8), 803-5

A Canadian research team recently reported a series of 7 consecutive patients with type 1 brittle diabetes who could achieve sustained excellent metabolic control in the absence of insulin therapy after ... [more ▼]

A Canadian research team recently reported a series of 7 consecutive patients with type 1 brittle diabetes who could achieve sustained excellent metabolic control in the absence of insulin therapy after successful islet transplantation. This exceptional success, which contrasts with previous less favourable results, is probably due to the transplantation of a higher number of islets of good quality and to the use of a new glucocorticoid-free immunosuppressive regimen. These remarkable results which provide proof of the principle that islet transplantation can be reproducibly successful, at least for one year, may raise new hope in patients with type 1 diabetes. However, the problem of supply and demand of islets is huge and will require a careful, and probably difficult, selection of the best candidates to benefit from this new therapeutic approach. [less ▲]

Detailed reference viewed: 12 (0 ULg)